gists
NICE U-turn on cancer drug despite price increase
June 27, 2014Sales and Marketing Cancer, Glivec, NHS, Novartis, gists
UK pricing watchdog NICE has performed a U-turn on Glivec (imatinib) by issuing new draft guidance recommending the drug, despite …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
